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expanded CD21- B cells in cGVHD patients also expressed
higher inhibitory receptors namely FCRL4, CD22 and CD85J,
chemokine receptors CD11c, CXCR3 and lower CD62L and
CCR7 compared with naïve (CD27-CD21+CD19+) and clas-
sical memory CD27+CD21+CD19+) B cells. Moreover, B cells
in patients with cGVHD had a lower proliferative potential
following B-cell receptor crosslinking compared with B cells
from patients with no GvHD or HC, a feature of exhaustion
associated with high expression of inhibitory receptors.
Finally, the frequencies of circulating CD21- B cells correlated
with cGvHD grade (r¼0.67; P ¼ .002) but not with time from
SCT (r¼0.28; P ¼ .15). These data suggest that CD21- B cells
may play a role in the pathogenesis of cGVHD and could be
used as as a marker of disease severity.55
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Chronic graft-versus-host disease (cGVHD) remains
a complication of allogeneic HCT and treatment remains
prednisone dependent with starting dose of 1mg/kg/day.
Rituximab shows efﬁcacy in steroid-refractory cGVHD sup-
porting B-cell pathogenesis. We hypothesized that anti-B cell
therapy delivered at cGVHD development is effective and
steroid-sparing. 35 patients (pts) with new-onset cGVHD,
requiring systemic steroid treatment at 1mg/kg/day, received
Rituximab 375-mg/m2 weekly x4 within ﬁrst month of
diagnosis. A second course was allowed if pts had less than
a partial response (PR) after 2 months.
Primary endpoints were six-month and 1y clinical
responses including steroid requirements. All 35 pts are
evaluable with 1.5y follow-up. Clinically meaningful
responses (deﬁned as pts with a PR or CR and prednisone
<0.25 mg/kg/day) were seen in 15/35 pts (43%, 13 CR; 2 PR)
at 6 months and remained 15/35 (43%, 11 CR, 4 PR) through
1y. There were 6 deaths from cGVHDwithin 1y of Rituximab.Table 1
Clinically meaningful responses (CR or PR and prednisone <0.25 mg/kg)
Responde
Median days to cGVHD 233 (136-
Pre-ritux CD19+ B cells/microliter 110 (rang
Pre-ritux naïve CD19+ CD38-, IgD+ CD27- B cells/
microliter
102 (0-11
Recovery of naïve B cells 1.5 y after Rituximab/microliter 63 (0-43
Pre-ritux IgG (mg/dl) 645 (224-
Pre-ritux BAFF (mg/dl) 2.8 (0.8-8
F/M pairs
n¼15
11 (73%)
9/15 FàM tested HY IgG positive preRitux All 11 res
became
seronegatOverall, cGVHD clinical response was predicted by naïve
CD19+CD38-IgD+CD27- B-cells pre-rituximab (p¼0.03), and
low BAFF (p¼0.007). B-cell-alloreactivity was assessed by HY
IgM, IgG, and HY speciﬁc B-cell quantiﬁcation. 15 cGVHD
patients were male with female donors (F/M) and 6 (38%)
tested HY IgM positive and 9 (56%) were HY IgG positive at
cGVHD diagnosis. Both HY IgM and IgG became undetectable
in all responders. In contrast, 3 of the 4 nonresponders
remained IgG HY positive and the other 1 redeveloped HY
IgG with cGVHD progression. Similarly, HY-antigen speciﬁc
B-cells were detected in 8/15 (53%) before rituximab and
recurred in 4/6 survivors with progression of cGVHD thus far.
This ﬁrst reported clinical trial of Rituximab and cortico-
steroids for new-onset cGVHD showed 46% clinically mean-
ingful responses through 1y with a steroid sparing effect. The
redevelopment of alloreactive B cells and HY IgG in associ-
ation with cGVHD progression suggests longer Rituximab
treatment-schedules or more potent B-cell inhibitors may
further improve cGVHD therapy.
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CD4+CD25+Foxp3+ regulatory T cells (Treg) play a central
role in the maintenance of immune tolerance. Impaired
recovery of Treg after HSCT is associated with the develop-
ment of cGVHD. In patients with cGVHD, Treg proliferate at
high levels but these cells are also highly susceptible to
apoptosis, leading to decreased survival and relative Treg
deﬁciency. To identify mechanisms that regulate Treg
susceptibility to apoptosis we used a new ﬂow cytometry-
based assay to measure mitochondrial membrane depolar-
ization in response to a panel of pro-apoptotic BH3 peptides
(BIM, BID, BAD, NOXA, PUMA, BMF, HRK). This allowed us to
compare BH3 peptide-induced mitochondrial membrane
depolarization (“priming”) in different T cell subsets; CD4
Treg, conventional CD4 T cells (CD4 Tcon), and CD8 T cells.
We also examined cytoplasmic expression of Bcl-2, Mcl1,
BclxL, Bim and cell surface expression of CD95 death receptor
(Fas). Functional susceptibility to apoptosis was measured
following in vitro stimulation with staurosporine or anti-rs n¼15 Nonresponders n ¼17 P-value
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Abstracts / Biol Blood Marrow Transplant 19 (2013) S129eS149 S141CD95. We studied peripheral blood from 54 patients with
hematologic malignancies >2 years post HSCT (39 with
cGVHD; 15 without cGVHD). In patients without cGVHD, BH3
priming was similar in Treg, Tcon and CD8. In contrast, Treg
and CD8 were more primed than Tcon in cGVHD when
challenged with BIM, BAD, PUMA, BMF and BAD + NOXA
peptides. In patients with cGVHD, Treg expressed higher
levels of Bim, BclxL and CD95 and lower levels of Bcl-2, but
there was no signiﬁcant difference in Mcl1. Consistent with
these observations, Treg were more susceptible than Tcon
and CD8 to both mitochondrial and death receptor pathway
apoptosis in vitro. Increased Treg susceptibility to apoptosis
in cGVHD therefore appears to be mediated primarily by
increased expression of CD95 and Bim and lower levels of
Bcl-2. Although Treg priming was increased overall in
cGVHD, examination of Treg in severe cGVHD actually
revealed less priming in this subset. This correlated with
increased Treg expression of Bcl-2 and Mcl1. Since the total
number of Treg is signiﬁcantly reduced in severe cGVHD,
these ﬁndings suggest that the remaining Treg are relatively
resistant to the mitochondrial pathway of apoptosis.
However, CD95 expression in Treg remains high in severe
cGVHD indicating persistent high-level apoptosis mediated
through the death receptor pathway. Administration of low
dose IL-2 to patients with severe cGVHD led to increased
expression of Bcl-2 and less susceptibility to both mito-
chondrial and death receptor pathway apoptosis. These
studies help deﬁne the complex and distinct pathways that
regulate survival in different T cell subsets, and changes in
these pathways that occur in patients with chronic GVHD.
These pathways play important roles in the maintenance of T
cell homeostasis and targeting these complex pathways can
provide new opportunities to promote immune tolerance
after allogeneic HSCT.57
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Background: Graft versus host disease (GVHD) and
infectious complications are major limiting factors to the
success of allogeneic (allo) hematopoietic cell trans-
plantation (HCT). CMV reactivation and disease lead to
morbidity and mortality, and potentially promote GVHD.
Primary infection commonly leads to latency, and viral
replication can be reactivated in the immunocompromised
state. Using a low mortality/low GVHD severity murine HCT
model, we assessed for a contributory role of MCMV in GVHD
development.
Methods: BALB/c mice were infected with either Smith
strain murine CMV (MCMV) (3104 PFU) or mock and
monitored for 24 weeks to establish latency. CMV seroposi-
tivity was conﬁrmed and HCTwas performed using sublethal
TBI (750cGy single dose) followed by i.v. administration of
7106 bonemarrow cells plus 3106 splenocytes from either
syngeneic (syn) BALB/c or allo B10.D2 donors. Recipients
were observed for survival and clinical GVHD. At day +100,lung, liver, gut, spleen were collected in surviving animals
and analyzed for pathology and cytokine expression; BALF
cellularity was assessed. Engraftment of allo donor cells was
conﬁrmed by PCR for D2Mit265 gene product size of 139bp
(BALB/c) versus 103bp (B10.D2) in recipient's splenic DNA, all
allo recipients being at least 60% donor chimera.
Results: Mortality (26.3 vs. 8.3%) and GVHD severity in allo
MCMV preinfected recipients was higher than in allo mock
controls. All syn recipients survived without evidence of
clinical disease. To assess the contribution of MCMV latency
and reactivation to GVHD pathology, allo recipients were
stratiﬁed by using MCMV IE1 gene expression at time of
analysis as an indicator for active replication. Pathologic
changes of lung and liver GVHD in IE-1+ recipients were
signiﬁcantly increased compared tomock controls (P< 0.01),
and were only slightly increased in IE-1-. None of the
changes were characteristic of active viral disease. No
signiﬁcant gut injury was seen in allo recipients and no
differences in pathology were seen among syn groups. In
IE1+ allo recipients, total cell and total CD4+ (but not CD8+) T
cell count in BALF were increased (p<0.05) when compared
with mock controls, as were protein expression of lung IFN-
gamma and liver TNF (p<0.05).
Conclusion: MCMV IE-1 expression indicating replicative
CMV reactivation is associated with increased GVHD severity
and strengthens the concept of CMV being not only a path-
ogen of potentially lethal viral disease but also as a driving
factor in GVHD development.58
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The placenta protects the fetus from the mother's
immune system. We have previously found that fetal
membrane cells (FMCs) isolated from term placenta prevent
alloreactivity in vitro. FMCs share many features with bone
marrow-derived mesenchymal stromal cells (MSCs), which
we previously introduced to treat severe acute graft-versus-
host disease (GVHD). Here, we tested FMCs for treatment of
steroid-refractory acute GVHD.
After two passages in culture, approximately 109 FMCs
were obtained from one single placenta, although not all
cells from passage 0 and passage 1 were used for expansion.
The FMCs were positive for CD29, CD44, CD73, CD90, CD105,
and CD49d but were negative for hematopoietic, endothelial,
and epithelial markers. Microsatellite polymorphism anal-
ysis showed that FMCs were of maternal origin. All FMCs
used showed normal karyotype.
Nine patients who had undergone hematopoietic stem
cell transplantation and who had developed steroid-refrac-
tory grade IIIeIV acute GVHDwere given 0.9e2.8 x 106 FMCs/
kg at 15 infusions. Median age was 57 years. There was no
